Literature DB >> 24403305

Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.

Seung Yeob Lee1, Jong Hee Shin, Kyung Hwa Park, Ju Hee Kim, Myung Geun Shin, Soon Pal Suh, Dong Wook Ryang, Soo Hyun Kim.   

Abstract

Colistin resistance remains rare among clinical isolates of Acinetobacter species. We noted the emergence of colistin-resistant bloodstream isolates of the Acinetobacter genomic species (GS) 13BJ/14TU from patients at a university hospital between 2003 and 2011. We report here, for the first time, the microbiological and molecular characteristics of these isolates, with clinical features of Acinetobacter GS 13BJ/14TU bacteremia. All 11 available patient isolates were correctly identified as Acinetobacter GS 13BJ/14TU using partial rpoB gene sequencing but were misidentified using the phenotypic methods Vitek 2 (mostly as Acinetobacter baumannii), MicroScan (mostly as A. baumannii/Acinetobacter haemolyticus), and the API 20 NE system (all as A. haemolyticus). Most isolates were susceptible to commonly used antibiotics, including carbapenems, but all were resistant to colistin, for which it is unknown whether the resistance is acquired or intrinsic. However, the fact that none of the patients had a history of colistin therapy strongly suggests that Acinetobacter GS 13BJ/14TU is innately resistant to colistin. The phylogenetic tree of multilocus sequence typing (MLST) showed that all 11 isolates formed a separate cluster from other Acinetobacter species and yielded five sequence types. However, pulsed-field gel electrophoresis (PFGE) revealed 11 distinct patterns, suggesting that the bacteremia had occurred sporadically. Four patients showed persistent bacteremia (6 to 17 days), and all 11 patients had excellent outcomes with cleared bacteremia, suggesting that patients with Acinetobacter GS 13BJ/14TU-associated bacteremia show a favorable outcome. These results emphasize the importance of precise species identification, especially regarding colistin resistance in Acinetobacter species. In addition, MLST offers another approach to the identification of Acinetobacter GS 13BJ/14TU, whereas PFGE is useful for genotyping for this species.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403305      PMCID: PMC3957785          DOI: 10.1128/JCM.02868-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens.

Authors:  Laurent Dortet; Patrick Legrand; Claude-James Soussy; Vincent Cattoir
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

2.  Distinct antimicrobial resistance patterns and antimicrobial resistance-harboring genes according to genomic species of Acinetobacter isolates.

Authors:  Yu Mi Lim; Kyeong Seob Shin; Jungmin Kim
Journal:  J Clin Microbiol       Date:  2006-12-27       Impact factor: 5.948

3.  Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii.

Authors:  Harald Seifert; Lucilla Dolzani; Raffaela Bressan; Tanny van der Reijden; Beppie van Strijen; Danuta Stefanik; Herre Heersma; Lenie Dijkshoorn
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii.

Authors:  Sergio G Bartual; Harald Seifert; Corinna Hippler; M Angeles Domínguez Luzon; Hilmar Wisplinghoff; Francisco Rodríguez-Valera
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Estimation of confidence in phylogeny: the complete-and-partial bootstrap technique.

Authors:  A Zharkikh; W H Li
Journal:  Mol Phylogenet Evol       Date:  1995-03       Impact factor: 4.286

6.  Evaluation of the ability of a commercial system to identify Acinetobacter genomic species.

Authors:  A T Bernards; J van der Toorn; C P van Boven; L Dijkshoorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

7.  Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.

Authors:  Matthew M Hsieh; James E Everhart; Danita D Byrd-Holt; John F Tisdale; Griffin P Rodgers
Journal:  Ann Intern Med       Date:  2007-04-03       Impact factor: 25.391

8.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

9.  Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species.

Authors:  Bernard La Scola; Vijay A K B Gundi; Atieh Khamis; Didier Raoult
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit.

Authors:  A Horrevorts; K Bergman; L Kollée; I Breuker; I Tjernberg; L Dijkshoorn
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

View more
  10 in total

1.  Emergence of IMP-34- and OXA-58-Producing Carbapenem-Resistant Acinetobacter colistiniresistens.

Authors:  Yuki Suzuki; Shiro Endo; Ryuichi Nakano; Akiyo Nakano; Kyoichi Saito; Risako Kakuta; Naoki Kakuta; Saori Horiuchi; Hisakazu Yano; Mitsuo Kaku
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.

Authors:  Rebekah Henry; Bethany Crane; David Powell; Deanna Deveson Lucas; Zhifeng Li; Jesús Aranda; Paul Harrison; Roger L Nation; Ben Adler; Marina Harper; John D Boyce; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-01-14       Impact factor: 5.790

3.  Differentiation of Acinetobacter Genomic Species 13BJ/14TU from Acinetobacter haemolyticus by Use of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS).

Authors:  Benjamin E W Toh; Hosam M Zowawi; Lenka Krizova; David L Paterson; Witchuda Kamolvit; Anton Y Peleg; Hanna Sidjabat; Alexandr Nemec; Valentin Pflüger; Charlotte A Huber
Journal:  J Clin Microbiol       Date:  2015-07-29       Impact factor: 5.948

4.  Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based VITEK MS system for the identification of Acinetobacter species from blood cultures: comparison with VITEK 2 and MicroScan systems.

Authors:  Seung Yeob Lee; Jong Hee Shin; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

5.  Comparison of biomarker based Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) and conventional methods in the identification of clinically relevant bacteria and yeast.

Authors:  Ali Kassim; Valentin Pflüger; Zul Premji; Claudia Daubenberger; Gunturu Revathi
Journal:  BMC Microbiol       Date:  2017-05-25       Impact factor: 3.605

6.  Acinetobacter baumannii: Epidemiological and Beta-Lactamase Data From Two Tertiary Academic Hospitals in Tshwane, South Africa.

Authors:  Michelle Lowe; Marthie M Ehlers; Farzana Ismail; Gisele Peirano; Piet J Becker; Johann D D Pitout; Marleen M Kock
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

7.  High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa - an update.

Authors:  Michelle Lowings; Marthie Magdaleen Ehlers; Andries William Dreyer; Marleen Magdalena Kock
Journal:  BMC Infect Dis       Date:  2015-11-14       Impact factor: 3.090

Review 8.  Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.

Authors:  Uh Jin Kim; Hee Kyung Kim; Joon Hwan An; Soo Kyung Cho; Kyung-Hwa Park; Hee-Chang Jang
Journal:  Chonnam Med J       Date:  2014-08-20

9.  Bacteremia due to Acinetobacter ursingii in infants: Reports of two cases.

Authors:  Nurhayat Yakut; Eda Kadayifci Kepenekli; Ayse Karaaslan; Serkan Atici; Gulsen Akkoc; Sevliya Ocal Demir; Ahmet Soysal; Mustafa Bakir
Journal:  Pan Afr Med J       Date:  2016-04-15

Review 10.  Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).

Authors:  William G Lima; Júlio C M Brito; Waleska S da Cruz Nizer
Journal:  Phytother Res       Date:  2020-09-18       Impact factor: 6.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.